Asset Management
Build Your Comparison
Side-by-side financial analysisStock Comparison
FHI vs IVZ vs JPM vs BLK vs BK
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
Banks - Diversified
Asset Management
Asset Management
FHI vs IVZ vs JPM vs BLK vs BK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Asset Management | Asset Management | Banks - Diversified | Asset Management | Asset Management |
| Market Cap | $4.49B | $12.50B | $908.57B | $173.68B | $100.01B |
| Revenue (TTM) | $1.86B | $6.59B | $280.33B | $24.22B | $40.44B |
| Net Income (TTM) | $399M | $-243M | $57.05B | $5.55B | $5.55B |
| Gross Margin | 51.5% | 50.7% | 60.0% | 50.5% | 48.9% |
| Operating Margin | 27.4% | -9.7% | 25.9% | 29.1% | 17.5% |
| Forward P/E | 11.6x | 10.9x | 14.6x | 19.7x | 16.2x |
| Total Debt | $457M | $10.12B | $942.38B | $15.00B | $33.88B |
| Cash & Equiv. | $584M | $1.98B | $343.34B | $11.47B | $131.52B |
FHI vs IVZ vs JPM vs BLK vs BK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Federated Hermes, I… (FHI) | 100 | 249.2 | +149.2% |
| Invesco Ltd. (IVZ) | 100 | 261.5 | +161.5% |
| JPMorgan Chase & Co. (JPM) | 100 | 345.8 | +245.8% |
| BlackRock, Inc. (BLK) | 100 | 193.0 | +93.0% |
| The Bank of New Yor… (BK) | 100 | 360.9 | +260.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FHI vs IVZ vs JPM vs BLK vs BK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FHI ranks third and is worth considering specifically for income & stability and growth exposure.
- Dividend streak 3 yrs, beta 0.70, yield 2.4%
- Rev growth 11.0%, EPS growth 58.8%
- Lower volatility, beta 0.70, Low D/E 36.2%, current ratio 41.26x
- Beta 0.70, yield 2.4%, current ratio 41.26x
IVZ carries the broadest edge in this set and is the clearest fit for value and dividends.
- Lower P/E (10.9x vs 16.2x)
- 3.0% yield, 4-year raise streak, vs BLK's 1.9%
- +96.9% vs BLK's +9.4%
JPM is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 481.2% 10Y total return vs BK's 285.3%
- PEG 0.83 vs BLK's 9.19
- NIM 2.2% vs FHI's 0.5%
BLK is the #2 pick in this set and the best alternative if growth and quality is your priority.
- 18.7% NII/revenue growth vs BK's 2.2%
- Efficiency ratio 0.3% vs IVZ's 0.5% (lower = leaner)
- Efficiency ratio 0.3% vs IVZ's 0.5%
Among these 5 stocks, BK doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% NII/revenue growth vs BK's 2.2% | |
| Value | Lower P/E (10.9x vs 16.2x) | |
| Quality / Margins | Efficiency ratio 0.3% vs IVZ's 0.5% (lower = leaner) | |
| Stability / Safety | Beta 0.70 vs IVZ's 1.61, lower leverage | |
| Dividends | 3.0% yield, 4-year raise streak, vs BLK's 1.9% | |
| Momentum (1Y) | +96.9% vs BLK's +9.4% | |
| Efficiency (ROA) | Efficiency ratio 0.3% vs IVZ's 0.5% |
FHI vs IVZ vs JPM vs BLK vs BK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FHI vs IVZ vs JPM vs BLK vs BK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
FHI leads in 2 of 6 categories
IVZ leads 1 • BK leads 1 • JPM leads 0 • BLK leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — JPM and BLK each lead in 2 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 150.7x FHI's $1.9B. BLK is the more profitable business, keeping 22.9% of every revenue dollar as net income compared to IVZ's -3.7%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.9B | $6.6B | $280.3B | $24.2B | $40.4B |
| EBITDAEarnings before interest/tax | $527M | $1.2B | $81.4B | $8.1B | $8.9B |
| Net IncomeAfter-tax profit | $399M | -$243M | $57.0B | $5.6B | $5.5B |
| Free Cash FlowCash after capex | $307M | $1.9B | $100.9B | $3.6B | $5.2B |
| Gross MarginGross profit ÷ Revenue | +51.5% | +50.7% | +60.0% | +50.5% | +48.9% |
| Operating MarginEBIT ÷ Revenue | +27.4% | -9.7% | +25.9% | +29.1% | +17.5% |
| Net MarginNet income ÷ Revenue | +21.4% | -3.7% | +20.4% | +22.9% | +13.7% |
| FCF MarginFCF ÷ Revenue | +16.5% | +28.5% | +36.0% | +14.8% | +12.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +1.6% | +34.2% | +16.0% | -22.7% | +25.3% |
Valuation Metrics
IVZ leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 11.5x trailing earnings, FHI trades at a 61% valuation discount to BLK's 29.6x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs BLK's 13.81x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $4.5B | $12.5B | $908.6B | $173.7B | $100.0B |
| Enterprise ValueMkt cap + debt − cash | $4.4B | $20.6B | $1.51T | $177.2B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | 11.51x | -17.58x | 16.22x | 29.65x | 19.15x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.56x | 10.91x | 14.60x | 19.74x | 16.16x |
| PEG RatioP/E ÷ EPS growth rate | 1.19x | — | 0.92x | 13.81x | 1.36x |
| EV / EBITDAEnterprise value multiple | 7.82x | 16.82x | 18.52x | 22.99x | 0.27x |
| Price / SalesMarket cap ÷ Revenue | 2.48x | 1.96x | 3.25x | 7.17x | 2.47x |
| Price / BookPrice ÷ Book value/share | 3.51x | 0.98x | 2.51x | 2.82x | 2.23x |
| Price / FCFMarket cap ÷ FCF | 15.23x | 8.68x | 9.01x | 46.33x | 19.32x |
Profitability & Efficiency
FHI leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
FHI delivers a 29.5% return on equity — every $100 of shareholder capital generates $30 in annual profit, vs $-2 for IVZ. BLK carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), FHI scores 8/9 vs BLK's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +29.5% | -1.7% | +15.9% | +9.9% | +12.5% |
| ROA (TTM)Return on assets | +18.2% | -0.9% | +1.3% | +3.6% | +1.2% |
| ROICReturn on invested capital | +24.1% | -2.3% | +4.5% | +7.5% | +6.4% |
| ROCEReturn on capital employed | +26.3% | -2.6% | +8.9% | +4.6% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 6 | 5 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.36x | 0.78x | 2.60x | 0.24x | 0.76x |
| Net DebtTotal debt minus cash | -$127M | $8.1B | $599.0B | $3.5B | -$97.6B |
| Cash & Equiv.Liquid assets | $584M | $2.0B | $343.3B | $11.5B | $131.5B |
| Total DebtShort + long-term debt | $457M | $10.1B | $942.4B | $15.0B | $33.9B |
| Interest CoverageEBIT ÷ Interest expense | 44.07x | -6.19x | 0.74x | 10.70x | 0.34x |
Total Returns (Dividends Reinvested)
BK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BK five years ago would be worth $31,197 today (with dividends reinvested), compared to $12,217 for IVZ. Over the past 12 months, IVZ leads with a +96.9% total return vs BLK's +9.4%. The 3-year compound annual growth rate (CAGR) favors BK at 49.3% vs BLK's 17.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.2% | +6.0% | +0.8% | -2.2% | +22.2% |
| 1-Year ReturnPast 12 months | +43.1% | +96.9% | +20.9% | +9.4% | +57.2% |
| 3-Year ReturnCumulative with dividends | +69.2% | +85.1% | +138.8% | +61.1% | +232.7% |
| 5-Year ReturnCumulative with dividends | +101.8% | +22.2% | +135.5% | +36.8% | +212.0% |
| 10-Year ReturnCumulative with dividends | +144.4% | +30.3% | +481.2% | +248.2% | +285.3% |
| CAGR (3Y)Annualised 3-year return | +19.2% | +22.8% | +33.7% | +17.2% | +49.3% |
Risk & Volatility
FHI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FHI is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than IVZ's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FHI currently trades 98.7% from its 52-week high vs BLK's 86.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.61x | 0.87x | 1.25x | 0.85x |
| 52-Week HighHighest price in past year | $59.83 | $29.82 | $338.09 | $1219.94 | $143.94 |
| 52-Week LowLowest price in past year | $41.71 | $14.48 | $269.72 | $917.39 | $87.41 |
| % of 52W HighCurrent price vs 52-week peak | +98.7% | +94.4% | +96.2% | +86.1% | +98.6% |
| RSI (14)Momentum oscillator 0–100 | 67.2 | 59.2 | 72.1 | 56.1 | 70.9 |
| Avg Volume (50D)Average daily shares traded | 734K | 4.3M | 7.4M | 600K | 2.8M |
Analyst Outlook
Evenly matched — IVZ and BLK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: FHI as "Hold", IVZ as "Hold", JPM as "Buy", BLK as "Buy", BK as "Buy". Consensus price targets imply 24.0% upside for BLK (target: $1302) vs -2.7% for FHI (target: $58). For income investors, IVZ offers the higher dividend yield at 2.96% vs BK's 1.45%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $57.50 | $30.06 | $339.75 | $1301.63 | $139.86 |
| # AnalystsCovering analysts | 21 | 28 | 61 | 33 | 29 |
| Dividend YieldAnnual dividend ÷ price | +2.4% | +3.0% | +1.8% | +1.9% | +1.4% |
| Dividend StreakConsecutive years of raises | 3 | 4 | 15 | 16 | 15 |
| Dividend / ShareAnnual DPS | $1.40 | $0.83 | $5.95 | $20.24 | $2.05 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.9% | +14.9% | +3.8% | +1.1% | +4.5% |
FHI leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). IVZ leads in 1 (Valuation Metrics). 2 tied.
FHI vs IVZ vs JPM vs BLK vs BK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FHI or IVZ or JPM or BLK or BK a better buy right now?
For growth investors, BlackRock, Inc.
(BLK) is the stronger pick with 18. 7% revenue growth year-over-year, versus 2. 2% for The Bank of New York Mellon Corporation (BK). Federated Hermes, Inc. (FHI) offers the better valuation at 11. 5x trailing P/E (11. 6x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FHI or IVZ or JPM or BLK or BK?
On trailing P/E, Federated Hermes, Inc.
(FHI) is the cheapest at 11. 5x versus BlackRock, Inc. at 29. 6x. On forward P/E, Invesco Ltd. is actually cheaper at 10. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus BlackRock, Inc. 's 9. 19x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — FHI or IVZ or JPM or BLK or BK?
Over the past 5 years, The Bank of New York Mellon Corporation (BK) delivered a total return of +212.
0%, compared to +22. 2% for Invesco Ltd. (IVZ). Over 10 years, the gap is even starker: JPM returned +481. 2% versus IVZ's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FHI or IVZ or JPM or BLK or BK?
By beta (market sensitivity over 5 years), Federated Hermes, Inc.
(FHI) is the lower-risk stock at 0. 70β versus Invesco Ltd. 's 1. 61β — meaning IVZ is approximately 131% more volatile than FHI relative to the S&P 500. On balance sheet safety, BlackRock, Inc. (BLK) carries a lower debt/equity ratio of 24% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — FHI or IVZ or JPM or BLK or BK?
By revenue growth (latest reported year), BlackRock, Inc.
(BLK) is pulling ahead at 18. 7% versus 2. 2% for The Bank of New York Mellon Corporation (BK). On earnings-per-share growth, the picture is similar: Federated Hermes, Inc. grew EPS 58. 8% year-over-year, compared to -235. 6% for Invesco Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FHI or IVZ or JPM or BLK or BK?
BlackRock, Inc.
(BLK) is the more profitable company, earning 22. 9% net margin versus -4. 4% for Invesco Ltd. — meaning it keeps 22. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FHI leads at 29. 5% versus -10. 9% for IVZ. At the gross margin level — before operating expenses — FHI leads at 73. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FHI or IVZ or JPM or BLK or BK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus BlackRock, Inc. 's 9. 19x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Invesco Ltd. (IVZ) trades at 10. 9x forward P/E versus 19. 7x for BlackRock, Inc. — 8. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLK: 24. 0% to $1301. 63.
08Which pays a better dividend — FHI or IVZ or JPM or BLK or BK?
All stocks in this comparison pay dividends.
Invesco Ltd. (IVZ) offers the highest yield at 3. 0%, versus 1. 4% for The Bank of New York Mellon Corporation (BK).
09Is FHI or IVZ or JPM or BLK or BK better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Invesco Ltd. (IVZ) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, IVZ: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FHI and IVZ and JPM and BLK and BK?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FHI is a small-cap deep-value stock; IVZ is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock; BLK is a mid-cap high-growth stock; BK is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.